During the last five years, there has been enormous progress in molecular imaging and radionuclide therapy of prostate cancer. Two molecular imaging agents (11C-choline and 1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid [18F-FACBC]) ([1][1],[2][2]) and one radionuclide therapy (223Ra-dichloride
No takes yet. Share an insight, caveat, or question.
Weber et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: